Introduction
It has long been suspected that interindividual variation in the ef®cacy and side-effects of medications may be in¯uenced by genetic factors [1] . Pharmacogenetics, de®ned as`the study of the role of genetics in drug response' [2] , is based on the tenet that`the genetic endowment of the individual, phenotypically expressed in protein structure, con®guration and concentration, may alter drug action in multiple ways' [3] . Until recently, the only pharmacogenetic phenomena known to in¯uence blood pressure response to antihypertensive therapy were single gene polymorphisms with large effects on the metabolism of a few drugs that are no longer widely used. Genes coding for the enzyme variants determining these discretely distributed differences in drug disposition have been identi®ed, and the responsible mutations within these genes are well characterized. With the mapping and sequencing of all human genes soon to be completed [4] , attention is turning to identi®cation and characterization of genes with more modest effects on drug action that contribute to continuously distributed variation in blood pressure responses to the antihypertensive medications now in common use. Identi®cation of these genes is being accelerated by technological advances that facilitate measurement of DNA sequence variation throughout the genome and by the discovery of genes contributing to interindividual differences in blood pressure level and the occurrence of hypertension [5±8] . Knowledge of genes that in¯uence the pharmacodynamic determinants of blood pressure response to antihypertensive medications has the potential to provide new insights not only into molecular mechanisms in¯uencing drug response, but also into the role that these genes may play in determining interindividual differences in blood pressure level and the occurrence of hypertension.
The objectives of this review are (i) to present pharmacogenetic concepts relevant to antihypertensive drug therapy; (ii) to consider the challenge of identifying individual genetic factors that contribute to differences in responses to antihypertensive medications; (iii) to describe classical pharmacogenetic investigations successful in identifying single gene polymorphisms with large effects on the metabolism of several antihypertensive drugs; (iv) to provide examples of candidate gene and genome scanning approaches now being applied to identify genes contributing to continuously distributed variation in blood pressure response to antihypertensive medications; and (v) to suggest developments likely in the future to expand the role of pharmacogenetics in the evaluation, treatment, and control of hypertension and its complications.
Basic concepts
A variety of mechanisms determine drug response (Fig. 1) . Pharmacokinetic mechanisms that determine the level of the drug in the blood, and ultimately at its target, include absorption of the drug, its distribution, excretion and metabolism. These mechanisms that determine the fate of the drug itself are distinguished from pharmacodynamic mechanisms that govern the interaction of the drug with its target and the subsequent cellular and systemic events that occur as a consequence of this interaction. Genetic variation that alters the structure, con®guration or quantity of any of the proteins involved in any of these mechanisms may contribute to interindividual variation in drug response.
When a standard dose of a drug is given to a group of individuals and an index of response is measured and plotted, several types of frequency distribution curves can be observed. Rarely, the distribution of responses is bimodal (Fig. 2) . Separate subpopulations with distinctly different drug responses suggest that a single factor, possibly segregation of alleles at a single genetic locus, has a large effect on drug response [9] . In contrast, for most drugs, the frequency distribution histogram for most measures of response is unimodal and bell-shaped, or a so-called`normal' or Gaussian distribution (Fig. 2) . Such a frequency distribution is consistent with multifactorial determination by effects of many genetic and environmental factors, with no single factor having a discernibly large effect on response. Clearly, when the distribution of responses is continuous and unimodal, it is more dif®cult to identify the effects of individual genes.
The challenge: heterogeneity of hypertension and antihypertensive drug responses Blood pressure levels are homeostatically maintained through complex interactions of many biochemical, physiological and anatomical traits organized into interrelated systems that exert redundant and counterbalancing pressor and depressor effects [10] . Although single factors may rarely cause blood pressure to deviate into the hypertensive range [11±13], most hypertension has a multifactorial aetiology that includes many genetic and environmental factors acting through the intermediate systems regulating blood pressure level [10] . Determinants of drug response. Genetic variation may contribute to interindividual differences in drug response by altering the structure, con®guration or quantity of proteins involved in pharmacokinetic or pharmacodynamic mechanisms determining drug response.
Antihypertensive drugs lower blood pressure by acting on speci®c targets within these intermediate systems ( [14, 15] . After dosages were titrated upward to achieve maximal effects, the percentage of patients in whom diastolic blood pressure was lowered to , 90 mmHg was similar among drugs and was only slightly greater than 50% for most drugs. As in other studies, the systolic and diastolic blood pressure responses to each drug were continuous and unimodally distributed [16, 22] ; the standard deviation of responses was similar in magnitude to the average response (approximately 10 mmHg); the range of responses was four-to-eight times greater than the average response [14±16,18]; and, for each drug, a sizable percentage of patients (10±20%) had paradoxical increases in blood pressure [16, 20, 22] . In most crossover comparisons of individual patients, response to one drug did not reliably predict response to another drug with a different mechanism of action [19±21,23,24] .
Progress towards identifying individual patient characteristics that predict blood pressure response prior to drug administration has been limited [25] . Although higher pretreatment blood pressure level is associated with greater antihypertensive drug response, the relationship is not speci®c to a particular antihypertensive drug or drug class, nor is it correlated with other patient characteristics [26, 27] . African Americans are reported to be more responsive to diuretics and calcium channel blockers and less responsive to â-blockers and angiotensin converting enzyme inhibitors than their Cauca- sian counterparts [14,25,28±30] ; however, neither gender, nor age, nor measures of body size has been found to predict response [25,31±34] . While some advocate measurement of plasma renin activity, indexed to sodium intake, to aid selection of antihypertensive drug therapy [35±37], other investigators ®nd this approach no more predictive than simply determined characteristics of race and age [38, 39] . Consequently, no pro®ling method is currently recommended as a basis for selection of antihypertensive drug therapy in individual patients [40] .
Classical pharmacogenetics: genes with large effects on drug metabolism.
Many classical pharmacogenetic investigations were initiated by serendipitous observation of an unexpected drug response, such as an exaggerated response or complete lack of response [41] . Unrelated individuals were then studied to verify a bimodal (or multimodal) distribution of the drug response. Next, families of individuals from the opposite extremes of the distributions were evaluated to determine whether the unusual response phenotype was transmitted from generation to generation in a pattern consistent with Mendelian inheritance of a single gene disorder. Finally, modern techniques of molecular genetics introduced in the late 1980s made it possible to clone genes responsible for such discretely distributed differences in drug responses [42] . Three of these single gene polymorphisms, summarized in Table 2 , are responsible for large interindividual differences in the metabolism of several antihypertensive agents. To our knowledge, no single gene polymorphisms have yet been identi®ed that have large effects on the absorption, distribution, or elimination of an antihypertensive drug.
Although single gene polymorphisms with large effects on drug metabolism have been at the forefront of pharmacogenetic investigation since its inception [41] , several factors diminish their relevance to contemporary clinical practice. First, the antihypertensive drugs metabolized by the polymorphic enzymes in Table 2 are no longer widely used. Second, newer antihypertensive agents found to be associated with large interpatient differences in therapeutic or toxic responses have been promptly withdrawn from the marketplace [80] . Third, methods to evaluate pathways of human drug metabolism in vitro [81] decrease the likelihood that new drugs largely metabolized by a single polymorphic enzyme will be introduced in the future [82] . Thus, pharmacodynamic mechanisms may play the predominant role in determining interindividual variation in blood pressure responses to the antihypertensive drugs now in common use. For example, the dose±response relationships for most modern antihypertensive drugs are relativelȳ at [83] with little, if any, correlation between steadystate drug levels and blood pressure-lowering effects [92, 93] . Consequently, there has been major interest in identifying genes that in¯uence the pharmacodynamic determinants of blood pressure response [94, 95] . Some progress is being made using candidate gene and genome scanning approaches.
Candidate gene studies
Adducin is an á/â heterodimeric cytoskeletal protein of the actin±spectrin lattice that is involved in signal transduction. Point mutations in the á-adducin gene explain up to 50% of the difference in blood pressure level between Milan normotensive and Milan hypertensive rats, a genetically hypertensive strain of rats in which increased renal sodium reabsorption plays a major pathophysiological role [96, 97] .
Cusi and colleagues reported linkage between markers at the human á-adducin locus and a gene contributing to hypertension [6] and found that a variant allele, characterized by a glycine-to-tryptophan change at amino acid 460 of á-adducin (Trp460), was signi®cantly more frequent in 477 hypertensive patients than in 332 normotensive control subjects. Because variants of the á-adducin gene are associated with increased renal tubular reabsorption of sodium and a volume-expanded sodium-sensitive form of hypertension in rats [98] , the investigators tested whether the Gly460Trp polymorphism was associated with differences in the antihypertensive response to diuretic treatment with furosemide (40 mg orally every 6 h for three doses) or hydrochlorothiazide (12.5±25 mg orally once daily for 8 weeks). In both protocols, the average blood pressure reduction was more than two times greater in heterozygotes carrying the Trp460 variant than in Gly460 homozygotes [6] . These ®ndings were con®rmed in a subsequent trial [99] , supporting the contention that the á-adducin polymorphism may be useful in identifying a subset of`salt-sensitive' hypertensive patients more responsive to diuretic therapy [6, 99] . The ®ndings also demonstrate how a gene that contributes to hypertension via a particular physiological mechanism (namely, increased renal sodium reabsorption and volume expansion) can serve as a candidate to in¯uence blood pressure response to an antihypertensive agent that targets this mechanism [100] .
Renin±angiotensin system genes
Hypertensive subjects carrying the Trp460 variant of á-adducin had lower mean plasma renin activity than Gly 460 homozygotes [6, 98, 99] , which is consistent with the notion that individuals with`low renin' hypertension are more responsive to diuretic therapy than those with normal or high renin hypertension [35, 101, 102] . Since the antihypertensive effectiveness of diuretic therapy is inversely related to the degree of counter-regulatory activation of the renin±angiotensin± aldosterone (RAA) system [35, 100, 103] , it is reasonable to hypothesize that variation in genes of the system [5,104±108] may be predictive of variation in blood pressure response. In partial support of this possibility, blood pressure responses to changes in dietary sodium intake were associated with polymorphisms of the genes coding for angiotensinogen and angiotensin converting enzyme (ACE) in some studies [109±113] . Unexpectedly, one of the allelic variants found to be associated with greater blood pressure reduction in response to dietary sodium restriction [109, 110] was previously associated with increased, not diminished, activity of the RAA system [5, 104, 105] .
Variation in genes of the RAA system has also been investigated in relation to antihypertensive responses to ACE inhibitors, â-blockers, and calcium channel blockers (Table 3) . Among hypertensive patients treated with ACE inhibitors (captopril, enalapril, lisinopril or perindopril), the T235 allele of the angiotensinogen gene was associated with signi®cantly greater systolic and diastolic blood pressure reductions in one study [114, 115] . However, the insertion/deletion (I/D) polymorphism of the ACE gene was not associated with differences in blood pressure responses to ACE inhibitors, a â-blocker (atenolol), or a dihydropyrindine calcium channel blocker (nifedipine) [114±117]; nor was a polymorphism of the angiotensin II (AT) receptor type 1 gene (A1166 to C) associated with differences in blood pressure response to ACE inhibitors [114] . Recently, a silent polymorphism in exon 5 of the gene coding for the á-subunit of G S -protein (FokI /±), which couples â-adrenoreceptors to cAMP production, was reported to be associated with differences in blood pressure response to â-blockers [118] .
A variety of other cardiovascular responses to antihypertensive drug therapy have been investigated in relation to polymorphisms in the genes coding for ACE and the AT 1 receptor (Table 4) . Overall, early results support the notion that genetic variation may have pleiotropic effects on numerous biochemical, physiologic, and anatomic measures of response to antihypertensive drug therapy [116,117,119±132] .
Genome scanning studies
For many traits, there may be no known polymorphic candidate gene or the list of plausible candidates may be so extensive as to render investigation of each one impractical. In these circumstances, a genome scanning approach can be used to ®rst identify chromosomal regions containing genes in¯uencing the trait, followed by positional cloning of candidate gene(s) within linked regions [133, 134] . Generally, such an approach employs highly polymorphic markers of DNA sequence variation throughout the genome measured in biologically related family members; linkage analyses then assess coinheritance of the markers with chromosomal regions containing genes in¯uencing the trait [135] . Because no prior knowledge or assumptions are required about gene function, one attractive feature of this approach is the possibility of identifying new genes previously unsuspected to in¯uence the trait. Moreover, the relative strength of linkage evidence accompanied by already-available knowledge about functions of genes within the linked regions, can serve to prioritize the subsequent search for functional mutations in the positionally implicated genes. However, because this method requires that the trait of interest be measured in a large number of related individuals (for example, sibling pairs), it poses dif®cult logistical challenges for antihypertensive drug response traits in humans.
To our knowledge, the only published genome-wide search for a pharmacogenetic trait locus employed a rodent model of genetic hypertension to identify a region of rat chromosome 2 containing a gene in¯u-encing blood pressure response to a dihydropyridine calcium channel blocker (PY108±068) [136] . In a backcross of F 1 generation rats with Lyon hypertensive rats, Vincent and colleagues performed linkage analyses using 40 different microsatellite markers measured over 15 chromosomes. For eight of 11 markers on chromosome 2, the reduction in blood pressure in response to the calcium channel blocker was signi®cantly greater in animals homozygous for the allele from hypertensive rats than in heterozygous rats. Maximum LOD scores of 4.4 and 4.1 for the systolic and diastolic blood pressure responses, respectively, were observed between two markers, D2Wox8 and D2Mit15, with variation at this locus accounting for 10.3 and 10.4% of variation in systolic and diastolic blood pressure responses, respectively [136] . In contrast, no effects of variation at this or other measured loci were seen on baseline blood pressure level or the blood pressure responses to a short-acting ganglionic blocking agent (trimethaphan camsylate) or an angiotensin II receptor antagonist (losartan) [136] .
Implication of a quantitative trait locus (QTL) on rat chromosome 2 that speci®cally affects blood pressure response to blockade of voltage-dependent L-type calcium channels is consistent with human and animal studies indicating that variation in calcium metabolism plays a role in determining differences in blood pressure level and the development of hypertension [137] . A gene coding for a protein involved in intracellular Table 3 Candidate gene studies of blood pressure response to antihypertensive drug therapy Antihypertensive drugs: ACE-I, angiotensin converting enzyme inhibitor; CCB-D, calcium channel blocker, dihydropyridine; BRB-S â calcium homeostasis [calmodulin-dependent protein kinase II-delta (Camk)] resides within the linked region and is therefore a candidate to in¯uence blood pressure response to the calcium channel antagonist. Although inferences to human hypertension are speculative, this study demonstrates the potential for genetic variation to contribute to differences in blood pressure response to speci®c antihypertensive agents and illustrates how a gene that in¯uences response to a drug with a known mechanism of action can implicate the blood pressureregulating system targeted by the drug as a contributor to the hypertensive state.
Future developments
Mapping and sequencing of all 50 000±100 000 genes in the human genome [138] are expected to be fully completed by the year 2003 [4] . Among the many methodological and technological advancements spawned by these accomplishments, several are likely to expand the role of pharmacogenetics in interventions against hypertension.
Genome-wide association studies using single nucleotide polymorphisms
One capability that will facilitate the discovery of genes in¯uencing drug responses in humans is the ability to perform genome-wide association studies using single nucleotide polymorphisms (SNPs). SNPs are positions in the genome at which two alternative nucleotides occur at an appreciable frequency (. 1%). As the most abundant form of polymorphism in the human genome, SNPs are estimated to occur every 500±1000 bp [139] ; thus, there are more than three million SNPs per human genome (which consists of approximately 3 3 10 9 bp). Genetic maps are now being constructed with . 2000 SNPs at an average spacing of , 2 cM between variable sites [140] (1 cM % 1000 000 bp). In contrast, the`variable number of tandem repeat' (VNTR) marker sets now used for genome-wide searches generally include 300±400 markers spaced every 10 cM. It has been calculated that a collection of 1000 biallelic SNPs provides the same power to detect a QTL as conventional sets of 300±400 multi-allelic VNTR markers [141] . Moreover, for linkage studies to achieve adequate power to detect QTLs with small or moderately sized effects, very large samples of related family members must be studied [142] , clearly, a sample design that is unfeasible for most drug response traits. Association studies that utilize biallelic SNPs measured in biologically unrelated individuals not only are inherently more powerful, but also require fewer study subjects, and thus are the only practical study design for genetic analyses of antihypertensive drug responses in humans. Dense SNP maps have the potential to reduce a genome-wide search for a QTL in¯uencing antihypertensive drug responses to a relatively straight-forward series of comparisons of allele frequencies between groups of unrelated individuals selected from opposite extremes of the drug response distribution [139] .
An additional development necessary to make this approach widely applicable is the ability to rapidly genotype large numbers of SNPs at a reasonable cost. Two-dimensional arrays of chemically synthesized oligonucleotides attached to a glass surface (so-called DNA chips) appear to offer one possible approach [140, 143] . Such chips are already commercially available to assess known mutations in the human cytochrome P450 genes encoding the CYP2D6 and CYP2C19 enzymes responsible for metabolizing many commonly prescribed drugs. Standardization and commercialization of this technology should reduce costs and extend its applicability [144, 145] . A further challenge is the development and implementation of ef®-cient methods of cataloging and analysing the massive amounts of genotypic data that can be generated [146] .
Genotyping in large-scale clinical trials
Collection and analysis of genotype information is likely to become a routine part of large antihypertensive drug trials designed to assess blood pressure lower- [23, 24] , a`waitand-see' approach to the prevention of target organ complications is dif®cult to defend. Genetic measurements, which need only be made once in a person's lifetime, appear to be well-suited for evaluation and potential use as predictors of clinical events that may take decades to develop but have their origins early in life.
Individualized drug therapy
An ultimate goal of pharmacogenetic knowledge is to advance beyond the current`one size ®ts all' approach to antihypertensive drug therapy to more individualized approaches. Since proteins are the targets of antihypertensive drugs, the complete mapping and sequencing of all genes in the human genome [4] implies that potential targets of virtually every antihypertensive drug will be discovered. The challenge will be to ascertain the functions of many newly discovered genes, assess the extent and impact of their polymorphisms, and identify those whose gene products are valid drug targets [149, 157, 158] . The latter task will be aided by identi®cation of genes that in¯uence disease activity, inasmuch as disease genes may be candidates to in¯uence drug response. Conversely, drug response genes may become candidates to in¯uence disease process. The ability to obtain complete`molecular pro®les' of disease and drug response genes in individual patients [159] should provide ef®cient and highly accurate methods to identify individuals prior to drug administration who are likely to have favourable or unfavourable responses to treatment with a particular drug or class of drugs [160] . Reliable methods to ensure that a drug is only administered to those in whom it will be effective and non-toxic may also serve to maintain the usefulness of drugs that are found to be toxic in a few but are ef®cacious in many others [161] .
Knowledge of genes that contribute to the disease process and genes that in¯uence drug responses will facilitate the development of new drugs and therapeutic approaches that are based on a deeper understanding of the molecular determinants of the disease and the response to therapy. Drugs that are more speci®c for the molecular characteristics of individual patients should contribute to greater ef®cacy and reduced toxicity. Certainly, the collection and analyses of unprecedented amounts of genetic information in the coming years has the potential to revolutionize the way drugs are developed and the approaches taken to diagnose, treat and prevent hypertension and its associated target organ diseases.
